A Phase I, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics of JMKX003801 in Healthy Participants
Latest Information Update: 01 Oct 2024
At a glance
- Drugs JMKX 003801 (Primary)
- Indications Gram-positive infections
- Focus Adverse reactions
- Sponsors Jemincare
Most Recent Events
- 26 Sep 2024 Status changed from not yet recruiting to recruiting.
- 12 Aug 2024 Status changed from planning to not yet recruiting.
- 28 Dec 2023 New trial record